Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Jurisich

Cardiovascular Disease Roseville, CA Doctor of Osteopathy

NPI 1629083407 CMS profile 301166

2 Medical Plaza Dr Ste 175, Roseville, CA 95661

Open in the dashboard

General payments

$19,371

307 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Jurisich of Roseville, CA is reported in the CMS Open Payments database as having received $19,371 across 307 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,056 29
2024 General $2,207 16
2023 General $893 22
2022 General $2,412 26
2021 General $2,230 60
2020 General $2,679 53
2019 General $2,893 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Jurisich
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Peter Jurisich were reported at $6,056. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Peter Jurisich Cardiovascular Disease median Middle half National median
2019 $2,893 $450 $127–$1,392 $163
2020 $2,679 $242 $77–$751 $114
2021 $2,230 $335 $101–$1,037 $132
2022 $2,412 $395 $121–$1,211 $149
2023 $893 $443 $136–$1,283 $160
2024 $2,207 $450 $136–$1,323 $164
2025 $6,056 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,043 34 payments
  2. Abbott Laboratories $3,546 75 payments
  3. Biosense Webster, Inc. $3,508 27 payments
  4. Medtronic Vascular, Inc. $2,779 21 payments
  5. Boston Scientific Corporation $2,255 10 payments
  6. Acutus Medical, Inc. $620 20 payments
  7. Biotronik Inc. $533 6 payments
  8. Janssen Pharmaceuticals, Inc $382 33 payments
  9. Sanofi-Aventis U.S. LLC $297 16 payments
  10. Atricure, Inc. $179 1 payment
  11. Other $1,229 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,580 279 payments
  2. Travel and Lodging $8,765 27 payments
  3. Education $26 1 payment
Products named General payments · program years 2019–2025
  1. Carto 3 $3,396 19 payments
  2. FARAPULSE $2,098 6 payments
  3. Micra Pacemakers $1,643 14 payments
  4. Arctic Front $1,403 10 payments
  5. MICRA Pacemakers $1,354 9 payments
  6. AVEIR $1,262 9 payments
  7. DiamondTemp $858 8 payments
  8. Acticor 7 VR-T DX $409 4 payments
  9. XARELTO $382 33 payments
  10. Unify Assura CRT Defibrillator $356 12 payments
  11. Other $4,508 163 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,678

Median for Cardiology: 2,533

Drug cost

$696,619

Median for Cardiology: $485,213

Branded share of claims

36.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 372 $494,497
Entresto Sacubitril/Valsartan Brand 47 $67,261
Xarelto Rivaroxaban Brand 28 $42,598
Multaq Dronedarone Hcl Brand 17 $35,995
Jardiance Empagliflozin Brand 15 $19,426
Farxiga Dapagliflozin Propanediol Brand 15 $12,633
Propafenone Hcl Er Propafenone Hcl Brand 35 $6,360
Metoprolol Succinate Generic 212 $3,683
Amiodarone Hcl Generic 167 $3,010
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 55 $2,216

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$243,191

Medicare's payments for the services billed

Medicare patients

1,126

Average age 77

Services billed

3,185

496 women, 630 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 56%
Arthritis 55%
Ischemic heart disease 43%
Heart failure 38%
Chronic kidney disease 35%
Diabetes 28%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

307 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record